PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Disease ReportsJuvenile arthritis
MeSH D001171 - juvenile arthritis
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D012216:Rheumatic diseases
$
Success rate
D001168:Arthritis
$
Success rate
D001327:Autoimmune diseases
$
Success rate
D001171: 
Juvenile arthritis
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
Abbott BiotherapeuticsAdalimumab Trudexa  2003-09-01   
Ibuprofen Ibu  1989-12-18   
Ibuprofen Ibuprofen  1985-06-14   
AbbVieAdalimumab Humira  2002-12-31 $10,615 M Q4/23-Q3/24 
Ibuprofen, Hydrocodone Vicoprofen  1997-09-23   
Able LaboratoriesNaproxen Naproxen  2003-08-22   
Accord HealthcareMethotrexate Methotrexate  2007-04-30   
Ajanta PharmaNaproxen, Esomeprazole strontium Naproxen Esomeprazole Magnesium  2022-10-06   
Alembic PharmaceuticalsDiclofenac Diclofenac  2022-07-27   
Methotrexate Methotrexate  2024-06-03   
Alkem LaboratoriesIbuprofen Ibuprofen  2021-09-13   
Famotidine, Ibuprofen Ibuprofen Famotidine  2021-08-03   
AllerganNaproxen Naproxen  1995-02-10   
Naproxen, Esomeprazole strontium Naproxen Esomeprazole Magnesium  2022-08-24   
Sulfasalazine Sulfasalazine  1982-01-01   
Diclofenac Diclofenac  1996-03-26   
Diclofenac, Misoprostol Diclofenac Misoprostol  2012-07-09   
Ibuprofen, Hydrocodone Hydrocodone Ibuprofen  2003-12-31   
Ibuprofen Ibuprofen  1985-09-06   
Oxycodone, Ibuprofen Oxycodone Ibuprofen  2007-11-26   
AlraIbuprofen Ibu-tab  1988-08-11   
Altaire PharmaceuticalsDiclofenac Diclofenac  2015-11-16   
1
2
3
4
5
6
...
14
>
Clinical Trials
Historical Success Rate
Phase 1
81%
13/16
Phase 2
55%
6/11
Phase 3
64%
30/47
Approved: 19Overall Success rate: 28%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Abbott Biotherapeutics
1
2
3
4
5
6
...
9
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use